HUTCHMED DRC (HCM) revenue breakdown
By segment, Oncology/Immunology segment is the largest at 52% of fiscal 2025 revenue, growing 32% a year over 7 years.
By product, Invoiced Goods-Distribution is the largest at 48% of fiscal 2025 revenue; License & Collaborations-Manufacturing supply grew fastest, 157% a year over 2 years.
Revenue by segment
Fiscal years, as HUTCHMED DRC reports them in its 10-K filings; fiscal 2025 total $549M.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology/Immunology segment | — | — | $41M | $27M | $30M | $120M | $164M | $529M | $363M | $286M | 52% |
| Other Ventures segment | — | — | $173M | $178M | $198M | $237M | $263M | $309M | $267M | $263M | 48% |
| Commercial Platform | $181M | $205M | — | — | — | — | — | — | — | — | — |
| Innovation Platform | $35M | $36M | — | — | — | — | — | — | — | — | — |
Revenue by product
Fiscal years, as HUTCHMED DRC reports them in its 10-K filings; fiscal 2025 total $549M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Invoiced Goods-Distribution | $181M | $203M | $161M | $176M | $198M | $237M | $263M | $309M | $267M | $263M | 48% |
| Invoiced Goods-Marketed Products | — | — | $3M | $8M | $11M | $34M | $57M | $83M | $128M | $101M | 18% |
| Other collaboration revenue -royalties | — | — | $261,000 | $3M | $5M | $15M | $26M | $32M | $71M | $68M | 12% |
| Services-Commercialization of Marketed Products | — | — | $12M | $3M | $4M | $27M | $41M | $49M | $52M | $45M | 8% |
| License & Collaborations-Manufacturing supply | — | — | — | — | — | — | — | $5M | $10M | $31M | 6% |
| License & Collaborations-Services | — | — | $18M | $16M | $10M | $19M | $24M | $80M | $58M | $28M | 5% |
| Other collaboration revenue -licensing | — | — | — | — | — | $24M | $15M | $279M | $43M | $12M | 2% |
| Services-Research and development | — | — | $8M | $494,000 | $491,000 | $525,000 | $507,000 | $481,000 | $471,000 | — | — |
| Services | $25M | $28M | — | — | — | — | — | — | — | — | — |
| Other collaboration revenue from licensing | — | — | $12M | — | — | — | — | — | — | — | — |
| Milestones (note (c)) | $10M | — | — | — | — | — | — | — | — | — | — |
| Milestones | — | $9M | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as HUTCHMED DRC reports them in its 10-K filings; fiscal 2025 total $549M.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| PRC | $485M | $452M | $407M | 74% |
| United States And Others | $353M | $178M | $141M | 26% |
Questions
Where does HUTCHMED DRC make its money?
In fiscal 2025, by segment: Oncology/Immunology segment $286M, Other Ventures segment $263M.
From HUTCHMED DRC's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.